Dabigatran Etexilate and Digoxin: Comparison as Clinical Probe Substrates for Evaluation of P-gp Inhibition

Clin Pharmacol Ther. 2018 Nov;104(5):788-792. doi: 10.1002/cpt.1213. Epub 2018 Sep 21.

¹ Department of Pharmacokinetics, Pharmacodynamics and Drug Metabolism, Merck & Co., Inc., Kenilworth, New Jersey, USA.
² Centre for Applied Pharmacokinetic Research, School of Health Sciences, The University of Manchester, Manchester, UK.
³ Quantitative Drug Disposition, GlaxoSmithKline plc, King of Prussia, Pennsylvania, USA.
⁴ Office of Research and Standards, Office of Generic Drugs, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, USA.

No abstract available

Publication types

ATP Binding Cassette Transporter, Subfamily B, Member 1 / antagonists & inhibitors*
ATP Binding Cassette Transporter, Subfamily B, Member 1 / metabolism
Biotransformation
Caco-2 Cells
Dabigatran / metabolism
Dabigatran / pharmacokinetics*
Digoxin / metabolism
Digoxin / pharmacokinetics*
Drug Interactions
Drug Stability
Humans
Intestinal Absorption / drug effects*
Risk Assessment